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Abstract
Background: The immune system strongly influences outcome in patients with ovarian cancer. In particular, the
absolute lymphocyte count in peripheral blood (ALC) and the presence of tumor-infiltrating lymphocytes (TIL) have
each been associated with favourable prognosis. However, the mechanistic relationships between ALC, TIL and
prognosis are poorly understood. We hypothesized that high ALC values might be associated with stronger tumor
immunity as manifested by increased TIL, decreased tumor burden and longer survival.
Methods: ALC values were collected from patient records ≥ 2 years before, during or after primary treatment for
high-grade serous ovarian cancer (HGSC). Lymphocyte subsets were assessed in peripheral blood by flow
cytometry. CD8+ and CD20+ TIL were assessed by immunohistochemistry.
Results: Overall, patients had normal ALC values two or more years prior to diagnosis of HGSC. These values were
not predictive of disease severity or survival upon subsequent development of HGSC. Rather, ALC declined upon
development of HGSC in proportion to disease burden. This decline involved all lymphocyte subsets. ALC
increased following surgery, remained stable during chemotherapy, but rarely recovered to pre-diagnostic levels.
ALC values recorded at diagnosis did not correlate with CD8+ or CD20+ TIL but were associated with progression-
free survival.
Conclusions: Patients with high intrinsic ALC values show no clinical or survival advantage upon subsequent
development of HGSC. ALC values at diagnosis are prognostic due to an association with disease burden rather
than TIL. Therapeutic enhancement of ALC may be necessary but not sufficient to improve survival in HGSC.
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Background
Ovarian cancer affects more than 225,000 women and
claims 140,000 lives world-wide each year (http://www.
cancerresearchuk.org). High-grade serous epithelial ovar-
ian cancer (HGSC) is the most common and lethal form,
representing approximately two thirds of cases [1]. The
large majority of HGSC cases are diagnosed at Stage III
or greater, owing to the lack of effective early detection
strategies [1,2]. Current standard care for advanced
HGSC is cytoreductive surgery and chemotherapy with
platinum-based agents (e.g., carboplatin) in combination
with taxanes (e.g., paclitaxel) [2]. While most cases of
HGSC are initially responsive to treatment, the majority
of patients experience recurrence within 1-3 years and
ultimately succumb to their disease [2]. Favorable prog-
nostic factors for HGSC include early stage and optimal
surgical de-bulking [2].
In addition to these standard prognostic factors, the host
immune response to ovarian cancer has a strong influence
on clinical outcomes [3,4]. In particular, the presence of
CD8+ tumor-infiltrating lymphocytes (TIL) is associated
with prolonged progression-free survival (PFS) and overall
survival [5-9]. Accordingly, other features of cytolytic
CD8+ T cell responses are also positively associated with
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any medium, provided the original work is properly cited.survival, including IFN-g,I L - 1 2 ,T N F - a, the cytolytic gran-
ule component TIA-1, Major Histocompatibility Complex
(MHC) class I, and others (reviewed in [4]). In addition to
CD8+ T cells, CD20+ tumor-infiltrating B cells are also
associated with survival in HGSC [9] and other cancers
[10]. Thus, as with many other human cancers, TIL and
associated factors show a clear association with clinical
outcomes in ovarian cancer.
In addition to TIL, a second immunological parameter
associated with outcome in ovarian cancer and other
cancers is the absolute lymphocyte count (ALC), which is
a measure of the number of circulating lymphocytes in
peripheral blood. In healthy individuals, ALC values
range from 1.0 to 4.0 Giga/L [11] and are under strong
genetic control, as revealed by twin studies [12]. An indi-
vidual’s ALC is relatively stable through life, deviating
significantly only during illness. Lymphopenia can be
induced by major infection or sepsis and has strong prog-
nostic significance in these settings [13]. Lymphopenia is
also common in many autoimmune diseases, including
Type 1 diabetes, rheumatoid arthritis, Sjögren’ss y n -
drome, systemic lupus erythematosus (SLE), Crohn’sd i s -
ease, and celiac disease [13]. In these settings, chronic
lymphopenia leads to continuous homeostatic lymphocy-
tic proliferation, which in turn may increase the likeli-
hood of developing autoreactive lymphocytes [13]. Given
the diverse array of conditions that can induce lympho-
penia, it is not surprising that the Baltimore Longitudinal
Study of Healthy Aging showed that low ALC predicted
death within 3 years from any cause [14]. Thus, despite
being a relatively crude measure, ALC serves as a useful
barometer of immune function and general health in
humans.
Cancer patients also frequently show decreased ALC
values at diagnosis (reviewed in [15]). In 1970, Riesco
reported that ALC was positively associated with the
“curability” of a variety of cancers [16]. Similar associa-
tions between ALC and survival have been reported for a
wide variety of epithelial, connective tissue and lymphoid
cancers [17], including ovarian cancer [18,19]. In addition
to survival, ALC has been associated with response to
various cancer treatments, including chemotherapy [20]
and autologous hematopoietic stem cell transplantation
for hematopoietic [15] and epithelial cancers [21,22].
Many researchers have speculated that ALC might
influence cancer outcomes through an immunological
mechanism. Indeed, in Riesco’s 1970 paper, he noted that
“these findings agree with the idea of the participation of
lymphocytes in the mechanism of the eventual phenom-
enon of anticancerous immunity” [16]. If so, then it
might be beneficial to attempt to increase ALC in
patients as a means to promote tumor immunity. Impor-
tantly, however, this concept has not been critically eval-
uated. It has yet to be determined whether ALC is a
marker versus mediator of favorable prognosis. To
address this issue, we investigated the relationship
between ALC, TIL and outcome in HGSC. Specifically,
we hypothesized that patients with high ALC values
might mount stronger immune responses against their
tumor, resulting in increased TIL and prolonged survival.
To gain insight into the causal relationship between ALC
and prognosis, we considered not only ALC values
recorded at the time of cancer diagnosis, but also intrin-
sic ALC values recorded two or more years prior to
diagnosis.
Methods
Patients, clinical data and immunological data
This study was approved by the Research Ethics Board of
the British Columbia Cancer Agency (BCCA) and Uni-
versity of British Columbia. Patients were admitted to the
BCCA with high-grade serous epithelial ovarian cancer
(HGSC) between January 2005 and January 2010. Inclu-
sion criteria included (a) availability of ALC data, and (b)
treatment with primary cytoreductive surgery followed
by chemotherapy with carboplatin with or without pacli-
taxel. Exclusion criteria included previous or concurrent
cancers, neoadjuvant chemotherapy, and delivery of
radiation therapy as part of first line treatment. Clinical
data including ALC values were obtained from the
BCCA’s Oncology Reporting System and Cancer Agency
Information System under the Research Ethics Board
approval obtained by the Cheryl Brown Ovarian Cancer
Outcomes Unit, which permits access to medical records
related to treatment of all ovarian cancer patients
admitted to the BCCA. Pre-diagnostic ALC values were
obtained from primary care physicians for 113 HGSC
patients (Cohort A, Table 1). Progression-free survival
was defined as the time from diagnosis to first recurrence
as defined by a combination of physical findings, radiolo-
gical evidence or increased CA125. Of the 113 HGSC
patients for whom pre-diagnostic ALC values were avail-
able, 80 also had pre-treatment ALC values available for
comparison.
The flow cytometry study involved blood samples col-
lected prospectively from 15 HGSC patients and 16 age-
matched cancer-free females. The TIL study involved
110 HGSC patients (Cohort B, Table 1) for whom mid-
chemotherapy ALC values were available and primary
tumor specimens had previously been stained and
scored for CD8+ and CD20+ TIL [7,9,23]. Cohorts A
and B were largely independent of each other, except
for an overlap of 18 patients.
Analysis of lymphocyte subsets by flow cytometry
PBMCs were stained for 30 min at room temperature with
the following antibodies: CD3-FITC/PECy7/APC (clone
HIT3a), CD4-APCH7 (clone RPA-T4), CD8-PerCP (clone
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(clone HI100), CD19-PE (clone SJ25C1), CD20-FITC
(clone 2H7), CD25-FITC (clone M-A251), CD56-APC
(clone B159), CD14APCH7 (clone M5E2) (all from BD
Pharmingen Canada, Mississauga, ON). FoxP3 was
detected by intracellular staining following the manufac-
turer’s instructions (FoxP3-PE, clone PCH101,
eBioscience, San Diego, CA). Samples were analyzed on a
BD Influx multi-channel flow cytometer. Data analysis was
performed using FlowJo software.
Statistical analysis
Statistical analysis was performed with GraphPad Prism
5.0 and included log-rank test for survival analysis; gen-
eration of Kaplan-Meier curves; Kruskal Wallis test;
Friedman ANOVA; Dunn’s post test; Mann-Whitney U
test; and Wilcoxon Signed Rank test, as indicated in the
text.
Results
ALC declines upon the development of ovarian cancer
To assess whether individuals with high intrinsic ALC
values might experience a more favorable prognosis
upon the development of HGSC, we studied a cohort of
HGSC patients for whom we obtained matched ALC
values recorded ≥ 2 years prior to diagnosis (referred to
as “pre-diagnostic ALC”)a n da tt h et i m eo fd i a g n o s i s
before any form of treatment (referred to as “pre-treat-
ment ALC”). All patients went on to receive standard
treatment consisting of primary cytoreductive surgery
followed by platinum- and taxane-based chemotherapy.
The mean pre-diagnostic ALC was 1.9 Giga/L, which
is consistent with the mean for healthy women (1.9-1.95
Giga/L) [11]. This indicates that HGSC patients have,
on average, normal ALC values prior to the clinical pre-
sentation of cancer. By contrast, the mean pre-treatment
ALC was significantly lower at 1.4 Giga/L (p <0 . 0 0 0 1
by Wilcoxon signed rank test), indicating that the devel-
opment of HGSC is associated with a marked decline in
ALC. The extent of ALC decline was proportionate to
disease severity. For example, advanced stage patients
underwent a greater decline in ALC than early stage
patients (median from 1.8 to 1.4 vs. 1.9 to 1.7 Giga/L;
Figure 1A). Likewise, patients who after primary surgery
were classified as having suboptimally debulked disease
(defined as any visible residual) had a lower pre-treat-
ment ALC than optimally debulked patients (defined as
no visible residual) (median from 1.8 to 1.4 vs. 1.8 to 1.8
Giga/L; Figure 1B). Similar results were seen when
patients were stratified according to the presence of
ascites (Figure 1C). Note that these relationships were
not causally related to treatment, since pre-treatment
ALC was recorded prior to surgery or chemotherapy.
Rather, the results indicate that patients with higher dis-
ease burden experience a greater decline in ALC from
their pre-diagnostic values.
ALC and lymphocyte subsets
To determine which lymphocyte subsets are reduced in
patients with low ALC values, we used flow cytometry to
analyze peripheral blood lymphocytes collected prior to
treatment from 15 HGSC patients as well as 16 age-
matched females with no personal history of cancer. As
expected, cancer patients trended toward a lower median
ALC than controls (1.5 vs. 2.0 Giga/L), although this did
not reach significance by Mann-Whitney test (p =0 . 0 5 5 )
(Figure 2). Nevertheless, patients showed normal mean
percentages of CD3+ T cells, CD3 + CD4+ T cells, CD3
+ CD8+ T cells, CD3+ CD4 + CD25+ FoxP3+ Treg-like
cells, CD3 + CD56+ NKT-like cells, and CD19 + CD20+
B cells (Figure 2). The only statistically significant differ-
ence was that cancer patients had a modestly decreased
percentage of NK-like cells (CD3-CD56+) compared to
c o n t r o l s( 8 %v s .1 3 %r e s p e c t i v e l y ,p = 0.019 by Mann-
Whitney test). Thus, there were no gross deficiencies in
lymphocyte subsets in HGSC patients.
Table 1 Clinicopathological features of patient cohorts.
Cohort A Cohort B
Total number of patients 113 Total number of patients 110
Age at surgery (years) Age at Surgery (years)
Mean 64.4 Mean 59.2
Standard deviation 10.4 Standard deviation 10.8
Range 40-88 Range 35-83
Median 65.5 Median 58.5
Progression-free survival (years) Disease-specific survival (years)
Mean 1.5 Mean 4.3
Standard deviation 1.0 Standard deviation 2.3
Range 0.1-5.0 Range 0.6-10.8
Median 1.2 Median 3.9
Grade Grade
101 0
242 7
39 73 9 8
2 or 3 (unspecified) 12 2 or 3 (unspecified) 5
Stage Stage
I7I 8
II 15 II 10
III 81 III 90
IV 7 IV 2
Unknown 3 Unknown 0
Cohort A includes patients for whom pre-diagnostic ALC values were
available. Cohort B includes patients for whom both ALC values and CD8+
and CD20+ TIL scores were available
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Page 3 of 12Figure 1 ALC declines upon development of HGSC in proportion to disease burden. Change in ALC from pre-diagnostic (preDx) to pre-
treatment (preTx) levels according to (A) stage of disease (pelvic involvement encompasses Stage I and II disease, peritoneal involvement is
seen in Stage III and IV patients), (B) surgical debulking status (no visible residual vs visible residual), or (C) presence of ascites. Statistical
significance measured by Kruskal-Wallis ANOVA and Dunn’s post test.
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Page 4 of 12Figure 2 Flow cytometric analysis of lymphocyte subsets in blood from controls and HGSC patients in comparison to ALC. PBMCs from
controls and cancer patients (pre-treatment) were stained for the indicated markers and run on a BD Influx Multi-channel Flow Cytometer.
Mann-Whitney U tests were performed to examine the differences between controls and cancer patients with respect to (A) CD3+, (B) CD3 +
CD4+, (C) CD4 + CD25 + FoxP3+, (D) CD3+ CD8+, (E) CD19 + CD20+, (F) CD3-CD56 + and (G) CD3+CD56 + lymphocytes and (H) ALC values
for each group.
Milne et al. Journal of Translational Medicine 2012, 10:33
http://www.translational-medicine.com/content/10/1/33
Page 5 of 12ALC and prognosis
We examined the relationship between ALC and pro-
gression-free survival (PFS) by stratifying patients into
quartiles based on their pre-diagnostic or pre-treatment
ALC values. For pre-diagnostic ALC values, patients in
the highest quartile showed equivalent PFS to patients
i nt h el o w e s tq u a r t i l e( p = 0.50; Figure 3A). By contrast,
for pre-treatment ALC values, patients in the highest
quartile (ALC ≥ 1.8 Giga/L) showed a mean PFS of 1.7
years compared to 1.0 years for patients in the lowest
quartile (ALC ≤ 1.0) (p < 0.0001) (Figure 3B). Thus,
HGSC patients with high intrinsic ALC values show no
apparent survival advantage upon the development of
HGSC. Rather, patients with high ALC values at the
time of diagnosis have a significantly longer PFS.
Effect of standard treatment on ALC
The preceding analyses indicated that patients with the
highest disease burden experienced the greatest decline in
ALC from pre-diagnostic to pre-treatment timepoints
(Figure 1). We therefore reasoned that surgery and che-
motherapy, by reducing disease burden, might promote
recovery of ALC. To address this possibility, we assessed
ALC values in the subset of patients for whom ALC data
was available across four clinical time points: pre-diagnos-
tic, pre-treatment (i.e., prior to primary surgery or che-
motherapy), pre-chemotherapy (i.e., post-surgery but prior
to chemotherapy), and at the mid point of chemotherapy
(pre-cycle 4). Similar to the preceding results, the median
pre-diagnostic ALC was 2.0 Giga/L and declined to a pre-
treatment median of 1.5 Giga/L (Figure 4A). The median
ALC increased to 1.7 Giga/L after primary surgery and
was maintained at 1.7 Giga/L during chemotherapy
(Figure 4A).
For comparison, we also evaluated changes in neutro-
phils. In contrast to ALC, them e d i a na b s o l u t en e u t r o -
phil count (ANC) increased from pre-diagnostic to pre-
treatment time points (3.2 vs. 4.8 Giga/L). The mean
ANC did not change significantly after surgery but
dropped sharply during chemotherapy (from 5.1 to 2.1
Giga/L) (Figure 4B), which is a common clinical
observation.
ALC values are not routinely recorded at our institu-
tion once standard treatment is completed, therefore it
was difficult to consistently obtain ALC values during
the post-treatment phase. Nonetheless, in the subset of
patients who were in remission > 1 year after surgery,
the mean ALC remained low at 1.5 Giga/L. In the sub-
set of patients who succumbed to their disease, ALC
declined dramatically to 1.0 Giga/L within a year of
death (data not shown).
The preceding results support the notion that stan-
dard treatment, by reducing disease burden, promotes
recovery of ALC, although rarely to pre-diagnostic
levels. We investigated whether the extent of ALC
recovery might be associated with prognosis. To this
end, we first assessed ALC values recorded during che-
motherapy, since this was the time point at which most
patients achieved maximal ALC recovery. Indeed, ALC
values recorded at the midpoint of chemotherapy were
strongly associated with PFS (Figure 4C). However, this
analysis did not measure ALC recovery per se, since it
included patients with low disease burden who had
experienced only minimal ALC decline at the time of
diagnosis. To reduce this confounding effect, we ana-
lyzed ALC recovery in suboptimally de-bulked patients.
As mentioned, this subgroup experienced the greatest
decline in ALC from pre-diagnostic to pre-treatment
levels (Figure 1B). During treatment, this subgroup
showed a wide range of ALC recovery, from 48% to
143% (data not shown). This indicates that even among
patients with high-risk disease, some undergo a more
robust immune recovery than others. Unexpectedly,
however, the extent of ALC recovery showed no associa-
tion with PFS (Figure 4D). This suggests that restoration
of normal lymphocyte levels during treatment does not
confer a survival advantage.
ALC and tumor-infiltrating lymphocytes
Collectively, our results indicate that ALC values recorded
at diagnosis or during treatment have strong prognostic
significance. To address whether this association might
have an immunological basis, we investigated the relation-
ship between ALC and TIL in a cohort of 110 HGSC
patients for whom primary tumor specimens were avail-
able. For this analysis, we used the average of the ALC
values recorded during chemotherapy, since this was the
most consistently available time point in this patient
cohort. We focused on CD8+ and CD20+ TIL, since these
lymphocyte subsets showed the strongest association with
survival in our previous TIL study [9]. Primary tumor
samples were stained with antibodies to CD8 and CD20,
and cases were scored as positive or negative for TIL
according to established criteria [7,9]. Consistent with our
prior report [9], a significant proportion of tumors were
positive for intraepithelial CD8+ TIL (73.1% 79/108), and
a smaller proportion contained intraepithelial CD20+ TIL
(19.4% 20/103). ALC values showed no association with
the presence of intraepithelial CD8+ TIL (p = 0.66, Mann-
Whitney) or CD20+ TIL (p = 0.37, Mann-Whitney)
(Figure 5). This was true for the entire cohort (Figure 5)
and after stratification according to surgical de-bulking
status (data not shown). Similar results were seen using
pre-treatment ALC values, although the sample size was
smaller due to the limited availability of pre-treatment
ALC values in this cohort (data not shown). Thus, ALC
and TIL appear to be independent parameters that are
both associated with outcome in HGSC.
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ALC is associated with survival in ovarian cancer and
many other cancers, but the mechanistic basis of this
association is poorly understood. We hypothesized that
HGSC patients with high intrinsic ALC values might
mount stronger anti-tumor immune responses, reflected
Figure 3 Relationship between ALC and clinical outcome in ovarian cancer. HGSC patients were stratified into high and low quartiles
based on ALC values recorded (A) ≤ 2 years prior to HGSC diagnosis, or (B) just prior to treatment. Kaplan Meier analysis was performed to
compare PFS between groups; significance was assessed with the log-rank test. N values represent the number of patients in the highest and
lowest quartiles only, the middle 2 quartiles have been omitted; panel B has a higher n value as not all patients with pre-diagnostic ALCs
available had pre-treatment values available.
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survival. Contrary to this hypothesis, we found that
intrinsic ALC values (measured ≥ 2 years prior to the
diagnosis of cancer) have no bearing on tumor burden or
progression-free survival upon the subsequent develop-
ment of HGSC. Instead, we found that ALC declines
upon development of HGSC to levels proportionate to
tumor burden. Accordingly, ALC values recorded at the
time of diagnosis are strongly associated with prognosis.
ALC values increase after cytoreductive surgery but
rarely return to intrinsic levels, indicating long-term
impairment of lymphoid homeostasis. Finally, we showed
that ALC is not associated with the presence of CD8+ or
CD20+ TIL. Collectively, our findings demonstrate that
ALC and TIL are independent immunological parameters
associated with outcome in HGSC. In the case of ALC,
this appears to reflect an association with disease burden
rather than an immunological mechanism.
To determine patients’ intrinsic ALC, we obtained
values that were recorded two or more years prior to
HGSC diagnosis. While the natural history of HGSC
remains poorly understood, the latency between disease
initiation and clinical diagn o s i si se s t i m a t e dt ob e3 - 4
years based on biomarker and modeling studies [24,25].
Thus, with a two-year threshold, some patients in our
cohort presumably harbored small occult cancers at the
time their pre-diagnostic ALC values were measured.
Nevertheless, we note that the mean pre-diagnostic ALC
for our cohort (1.9 Giga/L) was similar to the mean for
healthy women (1.9-1.95 Giga/L) [11] and in most cases
did not decline until ≤ 1 year prior to HGSC diagnosis. A
related caveat is that pre-diagnostic ALC values might
have been collected for reasons such as acute illness (e.g.,
infection) and hence might not reflect “intrinsic” ALC
values in all cases. That said, for several patients we were
able to obtain serial ALC values over several years.
Figure 4 Effect of surgery and chemotherapy on ALC and ANC and relationship to clinical outcome. Friedman test followed by Dunn’s
post test was used to analyze (A) ALC and (B) ANC values collected prior to diagnosis (PreDx), prior to surgical treatment (PreTx), immediately
prior to chemotherapy (PreChem) and immediately prior to the 4th cycle of chemotherapy (MidChem). For ALC, only the change from the pre-
diagnostic time point to pre-treatment was significant. For ANC, the only insignificant change was from the pre-treatment to pre-chemotherapy
time points. (C) ALC values recorded at the mid point of chemotherapy are associated with prolonged PFS by Kaplan-Meier analysis. (D) Extent
of ALC recovery at the mid-point of chemotherapy (relative to pre-diagnostic ALC) is not associated with PFS in suboptimally debulked patients
by Kaplan-Meier analysis.
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declining ≤ 1 year prior to HGSC diagnosis.
What mechanism(s) might underlie the decline in ALC
upon the development of HGSC or other cancers? Simi-
lar to the development of lymphopenia during sepsis,
lower ALC values might reflect a response to systemic
inflammation. Ovarian cancer is often accompanied by
systemic inflammation, as evidenced by increased neutro-
phil counts (Figure 4). Moreover, several markers of
inflammation have been associated with increased tumor
burden and/or adverse outcome in ovarian cancer,
including high neutrophil-to-lymphocyte ratio [19]; high
monocyte count [26]; elevated C-reactive protein and
hypoalbuminaemia [27]; and elevated IL-6 and IL-8 levels
Figure 5 Relationship between ALC and (A) CD8+ and (B) CD20+ TIL.T u m o r sw e r es c o r e da sp o s i t i v eo rn e g a t i v ef o rt h ei n d i c a t e dT I L
subpopulations. Average ALC values recorded during chemotherapy were compared by Mann-Whitney U test.
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values by several possible mechanisms. In mice, IL-6 has
been shown to induce Id1 expression in uncommitted
hematopoietic progenitors, thereby promoting myelopoi-
esis over lymphopoiesis [30]. Consistent with this, lym-
phopenia correlates strongly with increased serum levels
of IL-6, as well as soluble IL-2 receptor and TNF receptor
in soft tissue sarcomas [31]. In addition to inflammatory
cytokines, ovarian cancer and other carcinomas are also
associated with elevated levels of Vascular Endothelial
Growth Factor [32], which can inhibit T cell development
[33].
ALC might also decline due to apoptosis of lympho-
cytes. For example, during sepsis, lymphopenia is asso-
ciated with apoptosis-induced depletion of lymphocytes
and dendritic cells [34]. Lymphopenia has also been
attributed to lymphocyte apoptosis in pancreatitis [35]
and measles infection [36]. Finally, CD8+ T cells from
cancer patients have been shown to undergo apoptosis in
response to tumor-derived microvesicles expressing
tumor antigens, Fas ligand and MHC class I [37]. In sum-
mary, the decline in ALC observed in cancer patients
may reflect both reduced production and increased apop-
tosis of lymphoyctes. It is noteworthy that ALC rarely
recovers to pre-diagnostic levels in HGSC (Figure 4 and
data not shown). Similar results were seen in head and
neck cancer, even in patients with no evidence of disease
two or more years after treatment [38]. Thus, cancer can
lead to the long-term impairment of lymphoid homeosta-
sis, a condition that may need to be addressed for immu-
notherapy to be effective.
In contrast to our initial hypothesis, we failed to find
an association between ALC and TIL (Figure 5).
Although we only evaluated CD8+ and CD20+ TIL,
these two subsets are strongly associated with patient
survival and hence are most relevant to our hypothesis
[4-9]. Whether ALC values are associated with other
mechanisms of anti-tumor immunity, such as innate or
humoral responses, remains to be determined. Even so,
these other immune mechanisms have yet to show the
same prognostic significance as TIL. As for the issue of
why TIL densities vary among patients, previous work
in ovarian cancer has linked the presence of TIL to che-
mokine profiles in tumors [3], functional status of the
BRCA DNA repair pathway [7], and other factors
(reviewed in [4]). It appears these mechanisms have a
greater influence than ALC in regulating TIL responses.
Our results have implications for cancer immunother-
apy, in particular strategies designed to non-specifically
increase lymphocyte numbers in cancer patients [39].
For example, administration of IL-2 causes transient
lymphocytosis (increased ALC), which correlates with
tumor response in metastatic melanoma [40] and renal
cancer [41]. Administration of IL-2 prior to surgery can
prevent lymphopenia and provide possible survival bene-
fit in pancreatic [42], colorectal [43], and gastric cancer
[44]. In the latter study, IL-2 administration increased
both ALC and TIL, suggesting these two immune para-
meters can be enhanced together. IL-7 can also be used
to increase circulating lymphocytes and has the advan-
tage of being less toxic than IL-2. For example, cancer
patients treated with IL-7 experienced marked increases
in peripheral CD4+ and CD8+ T cells, resulting in a
rejuvenated circulating T-cell profile [45]. Finally, ALC
can also be increased through cell therapy. In the setting
of autologous hematopoietic stem cell transplantation
(AHSCT), the extent of ALC or T cell recovery has
been positively associated with survival in myeloma and
lymphoma, breast cancer, and ovarian cancer [15,21,22].
Based on these results, researchers at the Mayo Clinic
are investigating whether increasing the lymphocyte
content of the AHSCT cell product can improve clinical
outcomes in lymphoma [7,15].
Although the above approaches may have merit, it is
noteworthy that in the present study the extent of ALC
recovery after standard treatment had no bearing on
prognosis (at least in suboptimally de-bulked patients),
suggesting that enhancing ALC alone does not confer
survival benefit. This implies that interventions that sim-
ply increase ALC may not be sufficient to elicit effective
tumor immunity. A more promising goal may be to
develop strategies that not only increase ALC but, in the
process, skew lymphocyte recovery in favour of a
tumor-reactive repertoire.
Conclusions
Patients with high intrinsic ALC values showed no
advantage with respect to disease severity or progres-
sion-free survival upon development of HGSC. ALC
values recorded at the time of diagnosis were strongly
associated with disease burden and thus prognosis. ALC
values were not associated with the presence of TIL.
From a therapeutic perspective, our results suggest that
simply increasing ALC may not be sufficient to promote
clinically significant antitumor responses.
Abbreviations
ALC: Absolute lymphocyte count; ANC: Absolute neutrophils count; HGSC:
High grade serous carcinoma; TIL: Tumor infiltrating lymphocytes; PFS:
Progression free survival; AHSCT: Autologous hematopoietic stem cell
transplantation.
Acknowledgements
We thank the many patients who generously provided biospecimens and
clinical data; Rebecca Barnes and Jordan Wong for help with clinical data
acquisition and analysis; and Dr. Ron deLeeuw for helpful advice. The work
in this manuscript was funded by the U.S. Department of Defense, Ovarian
Cancer Research Program (OC080380) and the
British Columbia Cancer Foundation. The funding sources played no role in
the design; collection, analysis and interpretation of data; the writing of the
manuscript or the decision to submit.
Milne et al. Journal of Translational Medicine 2012, 10:33
http://www.translational-medicine.com/content/10/1/33
Page 10 of 12Author details
1Trev and Joyce Deeley Research Centre, BC Cancer Agency, Victoria, BC,
Canada.
2BC Cancer Agency, Victoria, BC, Canada.
3Department of
Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
4Genetic Pathology Evaluation Centre of the Prostate Research Centre,
Department of Pathology, Vancouver General Hospital, and Gynecology
Tumour Group, British Columbia Cancer Agency, Vancouver, BC, Canada.
5Department of Pathology, University of Toronto, Toronto, ON, Canada.
6Department of Pathology and Laboratory Medicine, University of Calgary,
Calgary Laboratory Services, Calgary, AB, Canada.
7Department of Medical
Genetics, University of British Columbia, Vancouver, BC, Canada.
Authors’ contributions
KM conceived the study and its design, acquired clinical data, analysed the
data and drafted the manuscript. CA acquired clinical data. JRW performed
FACS experiments and analysis. WS performed FACS experiments and
analysis. KD acquired and processed control blood and coordinated the
acquisition of WBC differentials. SEK contributed access to clinical
information associated with TMAs used and performed statistical analysis.
CBG provided access to TMAs for analysis. BC scored immunohistochemical
staining. MK scored immunohistochemical staining. BNH conceived the
study and its design and drafted the manuscript. All authors contributed to
the revision of the manuscript and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 October 2011 Accepted: 27 February 2012
Published: 27 February 2012
References
1. Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD,
Gilks CB: Differences in tumor type in low-stage versus high-stage
ovarian carcinomas. Int J Gynecol Pathol 2010, 29:203-211.
2. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, Sessa C,
Castiglione M: Newly diagnosed and relapsed epithelial ovarian
carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol 2010, 21(Suppl 5):v23-v30.
3. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M,
Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al:
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
N Engl J Med 2003, 348:203-213.
4. Nelson BH: The impact of T-cell immunity on ovarian cancer outcomes.
Immunol Rev 2008, 222:101-116.
5. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA,
Frosina D, Gnjatic S, Ambrosone C, et al: Intraepithelial CD8+ tumor-
infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are
associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci
USA 2005, 102:18538-18543.
6. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K,
Higuchi T, Yagi H, Takakura K, Minato N, et al: Programmed cell death 1
ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic
factors of human ovarian cancer. Proc Natl Acad Sci USA 2007,
104:3360-3365.
7. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D,
Kalloger S, Han G, Ceballos K, Cadungog MG, et al: Intraepithelial T cells
and prognosis in ovarian carcinoma: novel associations with stage,
tumor type, and BRCA1 loss. Mod Pathol 2009, 22:393-402.
8. Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA,
Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW:
Prognostic significance of tumor-infiltrating T-lymphocytes in primary
and metastatic lesions of advanced stage ovarian cancer. Cancer
Immunol Immunother 2009, 58:449-459.
9. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH,
Nelson BH: Systematic analysis of immune infiltrates in high-grade
serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive
prognostic factors. PLoS One 2009, 4:e6412.
10. Nelson BH: CD20+ B cells: the other tumor-infiltrating lymphocytes. J
Immunol 2010, 185:4977-4982.
11. Bain B, Seed M, Godsland I: Normal values for peripheral blood white cell
counts in women of four different ethnic origins. J Clin Pathol 1984,
37:188-193.
12. Evans DM, Frazer IH, Martin NG: Genetic and environmental causes of
variation in basal levels of blood cells. Twin Res 1999, 2:250-257.
13. Datta S, Sarvetnick N: Lymphocyte proliferation in immune-mediated
diseases. Trends Immunol 2009, 30:430-438.
14. Bender BS, Nagel JE, Adler WH, Andres R: Absolute peripheral blood
lymphocyte count and subsequent mortality of elderly men. The
Baltimore Longitudinal Study of Aging. J Am Geriatr Soc 1986, 34:649-654.
15. Porrata LF, Markovic SN: Is absolute lymphocyte count just another
prognostic factor in cancer? SRX Medicine 2010 2010 [http://www.hindawi.
com/archive/2010/812304/].
16. Riesco A: Five-year cancer cure: relation to total amount of peripheral
lymphocytes and neutrophils. Cancer 1970, 25:135-140.
17. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I,
Tredan O, Verweij J, Biron P, Labidi I, et al: Lymphopenia as a prognostic
factor for overall survival in advanced carcinomas, sarcomas, and
lymphomas. Cancer Res 2009, 69:5383-5391.
18. Wolff JP, de Oliveira CF: Lymphocytes in patients with ovarian cancer.
Obstet Gynecol 1975, 45:656-658.
19. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K: Pre-treatment
neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer
and predicts survival after treatment. Cancer Immunol Immunother 2009,
58:15-23.
20. Lissoni P, Brivio F, Fumagalli L, Messina G, Ghezzi V, Frontini L, Giani L,
Vaghi M, Ardizzoia A, Gardani GS: Efficacy of cancer chemotherapy in
relation to the pretreatment number of lymphocytes in patients with
metastatic solid tumors. Int J Biol Markers 2004, 19:135-140.
21. Nieto Y, Shpall EJ, McNiece IK, Nawaz S, Beaudet J, Rosinski S, Pellom J, Slat-
Vasquez V, McSweeney PA, Bearman SI, et al: Prognostic analysis of early
lymphocyte recovery in patients with advanced breast cancer receiving
high-dose chemotherapy with an autologous hematopoietic progenitor
cell transplant. Clin Cancer Res 2004, 10:5076-5086.
22. Ferrandina G, Pierelli L, Perillo A, Rutella S, Ludovisi M, Leone G, Mancuso S,
Scambia G: Lymphocyte recovery in advanced ovarian cancer patients
after high-dose chemotherapy and peripheral blood stem cell plus
growth factor support: clinical implications. Clin Cancer Res 2003,
9:195-200.
23. Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS,
Sahota R, Tran E, Webb JR, et al: Tumor-infiltrating T cells correlate with
NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One 2008, 3:
e3409.
24. Brown PO, Palmer C: The preclinical natural history of serous ovarian
cancer: defining the target for early detection. PLoS Med 2009, 6:
e1000114.
25. Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD,
Bergan L, Thornquist MD, Scholler N, Kim N, et al: Assessing lead time of
selected ovarian cancer biomarkers: a nested case-control study. J Natl
Cancer Inst 2010, 102:26-38.
26. Bishara S, Griffin M, Cargill A, Bali A, Gore ME, Kaye SB, Shepherd JH, Van
Trappen PO: Pre-treatment white blood cell subtypes as prognostic
indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2007, E-pub.
27. Sharma R, Hook J, Kumar M, Gabra H: Evaluation of an inflammation-
based prognostic score in patients with advanced ovarian cancer. Eur J
Cancer 2008, 44:251-256.
28. Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR,
Fuller AF, Goodman AK, Nikrui N, et al: Cytokines IL-1beta, IL-2, IL-6, IL-8,
MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer
and their relationship to treatment with paclitaxel. Int J Gynecol Cancer
2000, 10:33-41.
29. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA:
Interleukin-6 level in serum and ascites as a prognostic factor in
patients with epithelial ovarian cancer. Cancer 1994, 73:1882-1888.
30. Maeda K, Malykhin A, Teague-Weber BN, Sun XH, Farris AD, Coggeshall KM:
Interleukin-6 aborts lymphopoiesis and elevates production of myeloid
cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals. Blood
2009, 113:4534-4540.
31. Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J: Alterations of
routine blood tests in adult patients with soft tissue sarcomas:
Milne et al. Journal of Translational Medicine 2012, 10:33
http://www.translational-medicine.com/content/10/1/33
Page 11 of 12relationships to cytokine serum levels and prognostic significance. Ann
Oncol 2001, 12:1423-1432.
32. Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, Sugisaki Y:
Prognostic significance of vascular endothelial growth factor expression
in human ovarian carcinoma. Br J Cancer 2000, 83:196-203.
33. Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, Carbone DP:
Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis
associated with elevated levels of VEGF. Blood 2007, 110:624-631.
34. Turrel F, Guignant C, Venet F, Lepape A, Monneret G: Innovative
therapeutic strategies for restoring lymphocyte functions in septic
patients. Inflamm Allergy Drug Targets 2008, 7:181-186.
35. Takeyama Y, Takas K, Ueda T, Hori Y, Goshima M, Kuroda Y: Peripheral
lymphocyte reduction in severe acute pancreatitis is caused by
apoptotic cell death. J Gastrointest Surg 2000, 4:379-387.
36. Okada H, Kobune F, Sato TA, Kohama T, Takeuchi Y, Abe T, Takayama N,
Tsuchiya T, Tashiro M: Extensive lymphopenia due to apoptosis of
uninfected lymphocytes in acute measles patients. Arch Virol 2000,
145:905-920.
37. Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ,
Whiteside TL: Tumor-derived microvesicles promote regulatory T cell
expansion and induce apoptosis in tumor-reactive activated CD8+ T
lymphocytes. J Immunol 2009, 183:3720-3730.
38. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL: Imbalance in
absolute counts of T lymphocyte subsets in patients with head and
neck cancer and its relation to disease. Adv Otorhinolaryngol 2005,
62:161-172.
39. Overwijk WW, Schluns KS: Functions of gammaC cytokines in immune
homeostasis: current and potential clinical applications. Clin Immunol
2009, 132:153-165.
40. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA: Factors
associated with response to high-dose interleukin-2 in patients with
metastatic melanoma. J Clin Oncol 2001, , 19: 3477-3482.
41. Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A: Lymphocyte
counts independently predict overall survival in advanced cancer
patients: a biomarker for IL-2 immunotherapy. J Immunother 2003,
26:394-402.
42. Uggeri F, Caprotti R, De Grate L, Crippa S, Nobili C, Penati C, Romano F:
Short-term preoperative IL-2 immunotherapy in operable pancreatic
cancer: a randomized study. Hepatogastroenterology 2009, 56:861-865.
43. Lissoni P, Brivio F, Fumagalli L, Di Fede G, Brera G: Enhancement of the
efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by
pretreatment with IL-2 subcutaneous immunotherapy in metastatic
colorectal cancer patients with lymphocytopenia prior to therapy. In Vivo
2005, 19:1077-1080.
44. Romano F, Cesana G, Berselli M, Gaia Piacentini M, Caprotti R, Bovo G,
Uggeri F: Biological, histological, and clinical impact of preoperative IL-2
administration in radically operable gastric cancer patients. J Surg Oncol
2004, 88:240-247.
45. Sportes C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK,
Brown MR, Fleisher TA, Noel P, Maric I, et al: Phase I study of recombinant
human interleukin-7 administration in subjects with refractory
malignancy. Clin Cancer Res 2010, 16:727-735.
doi:10.1186/1479-5876-10-33
Cite this article as: Milne et al.: Absolute lymphocyte count is associated
with survival in ovarian cancer independent of tumor-infiltrating
lymphocytes. Journal of Translational Medicine 2012 10:33.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Milne et al. Journal of Translational Medicine 2012, 10:33
http://www.translational-medicine.com/content/10/1/33
Page 12 of 12